Comparative characterization of S6 kinase &amp;alpha; and &amp;beta; isoforms expression in mammalian tissues

Savinska, L. O.; Kijamova, R. G.; Pogrebnoy, P; Ovсharenko, G. V.; Gout, Ivan; Filonenko, Valeriy

doi:10.7124/bc.0005c7

Cited by 18 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our data S6K1 and S6K2 have a tissue specific expression profile with the highest level in brain and testis respectively [14]. Analysis of S6Ks expression in tumor cell lines and tumour tissues revealed a sufficiently increased level of S6K1 and S6K2 in breast tumors [15].…”

mentioning

confidence: 50%

PI3K/mTOR/S6K signaling pathway – new players and new functional links

Filonenko

2013

Biopolym. Cell

Self Cite

View full text Add to dashboard Cite

This review summarizes experimental data related to the studies of PI3K/mTOR/S6K signaling conducted at the department of cell signaling. Analysis of novel S6Ks protein-protein interactions provided valuable information for understanding molecular mechanisms of regulation of S6Ks functional activity and subcellular localization mediated by PKC, CK2 and ROC1 ubiquitin ligase. We discuss the identification and functional analysis of novel isoform of ribosomal protein S6 kinase -S6K2 and of mTOR kinase -mTORb, as well as their oncogenic properties. Identification of CoA synthase responsible for last two steps in CoA biosynthesis and characterization of its interactions with S6K1 and other signaling molecules uncovere a potential link between mTOR/S6K signaling pathway and energy metabolism through regulation of CoA biosynthesis. The data concerning new molecular mechanisms of CoA synthase regulation are presented.

show abstract

mentioning

confidence: 50%

PI3K/mTOR/S6K signaling pathway – new players and new functional links

Filonenko

2013

Biopolym. Cell

Self Cite

View full text Add to dashboard Cite

show abstract

“…To block non-specific staining the coverslips were incubated in a blocking solution (10% fetal calf serum in PBS) for 30 min at 37 °C. The cells were immunostained with rabbit polyclonal antibodies against the S6K1 C-terminus [25] diluted 1 : 100 in PBS overnight at 4 °C, followed by incubation with secondary FITC-labeled anti-rabbit antibodies (Jackson ImmunoResearch) diluted 1 : 400 in PBS. Thereafter, the samples were mounted on microscope slides using the Mowiol medium (Sigma) containing 2.5% DABCO (Sigma) and 0.5 mg/ml of DAPI (Pierce).…”

Section: Methodsmentioning

confidence: 99%

“…Rabbit polyclonal antibodies and mouse monoclonal antibodies (C3/10) specific to the C-terminal region of S6K1 (amino acids 453-525 in p85-S6K1) were generated as described in [25,26]. The β-actin antibody was obtained from Sigma-Aldrich.…”

Section: Methodsmentioning

confidence: 99%

The Р60-S6K1 isoform of ribosomal protein S6 kinase 1 is a product of alternative mRNA translation

Zaiets¹,

Sivchenko²,

Хоруженко³

et al. 2018

Ukr.Biochem.J.

Self Cite

View full text Add to dashboard Cite

Ribosomal protein S6 kinase 1 (S6K1) is a well-known downstream effector of mTORC1 (mechanistic target of rapamycin complex 1) participating primarily in the regulationA number of downstream effects of mTORC1, including protein biosynthesis, cell growth, proliferation and survival [4,5] are mediated via ribosomal protein S6 kinase 1 (S6K1), a well-studied mTORC1 substrate.The S6K1 gene (RPS6KB1) was shown to encode two well-known S6K1 isoforms, p85-S6K1 and p70-S6K1, that differ only by the presence of the Nterminal 23 a.a. extension in p85-S6K1 due to the use of alternative (the first and second ATG) translational start sites [6]. Recently, it has been discovered that the splicing factor SF2/ASF promotes the expression of the oncogenic and the only known S6K1 splice variant termed p31-S6K1 or S6K1-isoform 2 that is truncated from the C-terminus [7]. A mechanism underlying oncogenic properties of p31-S6K1 is unclear but it seems to be kinase-independent, since the kinase domain of the given isoform is severely truncated. e x p e r i m e n T a l w o r K S e x p e r i m e n T a l w o r K S

show abstract

“…Development of hybridoma. Hybridoma development has been performed according to the protocol published in [18,19]. As an antigen for immunization S6K1 N-terminal recombinant peptide F1 has been used.…”

mentioning

confidence: 99%

“…The selected hybridomas were subcloned using limiting dilution method. For further characterization of the generated S6K1 specific antibodies the hybridoma culture supernatant or IgGs purified from ascitic fluid were used [18].…”

mentioning

confidence: 99%

Generation of monoclonal antibodies specific to ribosomal protein S6 kinase 1

et al. 2012

Self Cite

View full text Add to dashboard Cite

The aim of this study was to produce monoclonal antibodies directed to the N-terminal regulatory region of S6K1, which shows very low homology to S6K2. Methods. Hybridoma technology, ELISA, Western blot, Immunoprecipitation. Results. Three hybridoma clones (A1, A2 and A3) producing mAbs specific to ribosomal protein S6 kinase 1 have been generated. Specificity of mAbs has been confirmed by Western blot and immunoprecipitation technique. Conclusions. The obtained antibodies are suitable for elucidating signal transduction pathways involving S6K1

show abstract

Comparative characterization of S6 kinase α and β isoforms expression in mammalian tissues

Cited by 18 publications

References 24 publications

PI3K/mTOR/S6K signaling pathway – new players and new functional links

PI3K/mTOR/S6K signaling pathway – new players and new functional links

The Р60-S6K1 isoform of ribosomal protein S6 kinase 1 is a product of alternative mRNA translation

Generation of monoclonal antibodies specific to ribosomal protein S6 kinase 1

Contact Info

Product

Resources

About